Literature DB >> 33023944

Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity.

Ophir Shani1, Tatiana Vorobyov1, Lea Monteran1, Dor Lavie1, Noam Cohen1, Yael Raz1, Galia Tsarfaty2, Camila Avivi3, Iris Barshack3, Neta Erez4.   

Abstract

Lungs are one of the main sites of breast cancer metastasis. The metastatic microenvironment is essential to facilitate growth of disseminated tumor cells. Cancer-associated fibroblasts (CAF) are prominent players in the microenvironment of breast cancer. However, their role in the formation of a permissive metastatic niche is unresolved. Here we show that IL33 is upregulated in metastases-associated fibroblasts in mouse models of spontaneous breast cancer metastasis and in patients with breast cancer with lung metastasis. Upregulation of IL33 instigated type 2 inflammation in the metastatic microenvironment and mediated recruitment of eosinophils, neutrophils, and inflammatory monocytes to lung metastases. Importantly, targeting of IL33 in vivo resulted in inhibition of lung metastasis and significant attenuation of immune cell recruitment and type 2 immunity. These findings demonstrate a key function of IL33 in facilitating lung metastatic relapse by modulating the immune microenvironment. Our study shows a novel interaction axis between CAF and immune cells and reveals the central role of CAF in establishing a hospitable inflammatory niche in lung metastasis. SIGNIFICANCE: This study elucidates a novel role for fibroblast-derived IL33 in facilitating breast cancer lung metastasis by modifying the immune microenvironment at the metastatic niche toward type 2 inflammation. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33023944      PMCID: PMC7611300          DOI: 10.1158/0008-5472.CAN-20-2116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

2.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.

Authors:  Donye Dominguez; Cong Ye; Zhe Geng; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Long Wang; Zhuoli Zhang; Yi Zhang; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2016-12-23       Impact factor: 5.422

3.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Authors:  Neta Erez; Morgan Truitt; Peter Olson; Sarah Tuttleton Arron; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

4.  A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma.

Authors:  M Kobayashi; H Kobayashi; R B Pollard; F Suzuki
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

5.  IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Authors:  Kelly Kersten; Chris W Doornebal; Seth B Coffelt; Jorieke Weiden; Kim Vrijland; Cheei-Sing Hau; Niels J M Verstegen; Metamia Ciampricotti; Lukas J A C Hawinkels; Jos Jonkers; Karin E de Visser
Journal:  Nature       Date:  2015-03-30       Impact factor: 49.962

6.  Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.

Authors:  N Cohen; O Shani; Y Raz; Y Sharon; D Hoffman; L Abramovitz; N Erez
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 7.  The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.

Authors:  Jean-Jacques Fournié; Mary Poupot
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

8.  Evolution of fibroblasts in the lung metastatic microenvironment is driven by stage-specific transcriptional plasticity.

Authors:  Ophir Shani; Yael Raz; Lea Monteran; Ye'ela Scharff; Oshrat Levi-Galibov; Or Megides; Hila Shacham; Noam Cohen; Dana Silverbush; Camilla Avivi; Roded Sharan; Asaf Madi; Ruth Scherz-Shouval; Iris Barshack; Ilan Tsarfaty; Neta Erez
Journal:  Elife       Date:  2021-06-25       Impact factor: 8.140

9.  The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?

Authors:  Christine Moussion; Nathalie Ortega; Jean-Philippe Girard
Journal:  PLoS One       Date:  2008-10-06       Impact factor: 3.240

10.  Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis.

Authors:  Jie Li; Cun Liu; Yi Chen; Chundi Gao; Miyuan Wang; Xiaoran Ma; Wenfeng Zhang; Jing Zhuang; Yan Yao; Changgang Sun
Journal:  Front Genet       Date:  2019-11-12       Impact factor: 4.599

View more
  15 in total

Review 1.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

2.  A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors.

Authors:  Yi Lu; Dan Li; Yixin Cao; Leqian Ying; Qing Tao; Fen Xiong; Zhangmin Hu; Yufei Yang; Xuehan Qiao; Chen Peng; Dongqin Zhu; Deqiang Wang; Xiaoqin Li
Journal:  Front Cell Dev Biol       Date:  2022-04-26

Review 3.  Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy.

Authors:  Richard Lee Barrett; Ellen Puré
Journal:  Elife       Date:  2020-12-28       Impact factor: 8.140

4.  Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.

Authors:  Hanne Locy; Stefaan Verhulst; Wilfried Cools; Wim Waelput; Stefanie Brock; Louise Cras; Ann Schiettecatte; Jan Jonckheere; Leo A van Grunsven; Marian Vanhoeij; Kris Thielemans; Karine Breckpot
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 5.  Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures.

Authors:  Bing Feng; Jianzhong Wu; Bo Shen; Feng Jiang; Jifeng Feng
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

Review 6.  The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape.

Authors:  Mi-Ran Choi; Jeffrey A Sosman; Bin Zhang
Journal:  Cancers (Basel)       Date:  2021-06-30       Impact factor: 6.639

7.  Identification of m6A-Associated Gene DST as a Prognostic and Immune-Associated Biomarker in Breast Cancer Patients.

Authors:  Xiangyuan Qiu; Xinying Li; Yuanliang Yan; Yuan Cai; Qiuju Liang; Bi Peng; Zhijie Xu; Muzhang Xiao; Fada Xia; Jinwu Peng
Journal:  Int J Gen Med       Date:  2022-01-12

8.  Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma.

Authors:  Tyler Risom; David R Glass; Inna Averbukh; Candace C Liu; Alex Baranski; Adam Kagel; Erin F McCaffrey; Noah F Greenwald; Belén Rivero-Gutiérrez; Siri H Strand; Sushama Varma; Alex Kong; Leeat Keren; Sucheta Srivastava; Chunfang Zhu; Zumana Khair; Deborah J Veis; Katherine Deschryver; Sujay Vennam; Carlo Maley; E Shelley Hwang; Jeffrey R Marks; Sean C Bendall; Graham A Colditz; Robert B West; Michael Angelo
Journal:  Cell       Date:  2022-01-20       Impact factor: 41.582

Review 9.  CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion.

Authors:  Gurcan Gunaydin
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

Review 10.  The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment.

Authors:  Vladimir Mulens-Arias; José Manuel Rojas; Domingo F Barber
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.